Santiago Viteri/psmmc.com
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Santiago Viteri, Medical Director at UOMi Cancer Center and Chief Executive Officer at Pratia Sirius, reshared a post on LinkedIn by International Association for the Study of Lung Cancer adding:
“Negative results communication is key to having a better understanding od scientific problems.
As an investigator of the BR.31 trial, I am happy to contribute to evaluate the effect of adjuvant antiPD1 in non-small cell lung cancer (NSCLC).”
Quoting International Association for the Study of Lung Cancer’s post:
“Check out the latest findings from the BR.31 trial that were presented at the 2024 ESMO Congress.
Visit ILCN for a recap.”
For more updates, follow OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 3, 2025, 20:48
Sep 3, 2025, 20:35
Sep 3, 2025, 20:10
Sep 3, 2025, 19:42
Sep 3, 2025, 18:59
Sep 3, 2025, 18:01
Sep 3, 2025, 17:26
Sep 3, 2025, 16:34